


AMENDED CLAIMS

[received by the International Bureau on 16 May 2005 (16.05.2005)
original claims 1, 4 and 7 replaced by amended claims of same number ; all other claims, unchanged.]


+ STATEMENT

WHAT IS CLAIMED IS:

1. A compound of the following formula:




where $A = \text{---}(\text{CH}_2)_n\text{---}$, $n = 0, 1, 2$;



A is not necessarily equal to C ;

wherein R_1, R_2, R_3 and R_4 are independently selected from the group consisting of C_{2-4} hydroxyalkyl, C_{2-4} aminoalkyl, trifluoromethyl, pentafluoroethyl, phenyl, naphthyl, benzyl, biphenyl, phenethyl,


piperidinyl, methylpiperidinyl, ethylpiperidinyl, indenyl, 2,3-dihydroindenyl, $\text{C}_4\text{--C}_7$ cycloalkyl or cycloalkenyl, indoyl, methylindoyl, ethylindoyl, and substituted five-membered aromatic heterocyclic rings of the following formulas:




2. The compound according to claim 1, wherein:



A is not necessarily equal to C; and



3. The compound according to claim 1, wherein:



4. The compound according to claim 2 or 3, wherein:

R_1 and R_4 are selected from the group consisting of hydroxyethyl, hydroxypropyl, hydroxybutyl, amino, aminoethyl, aminopropyl, aminobutyl, phenyl, anilino, hydroxyphenyl, and aminophenethyl;


R_2 and R_3 are selected from the group consisting of anilino, aminoanilino, phenethyl and hydroxyphenethyl,

5. A compound selected from the group consisting of:

Compound No.


Structure

1




Compound No.**Structure**

50



51



6. The compound according to any one of claims 1 to 5, which can noncovalently bind to antibodies.

7. The compound according to any one of claims 1 to 4 which can noncovalently bind to antibodies wherein one, two, three or all of the substituents R_1 , R_2 , R_3 , R_4 is



8. The compound according to claim 6 or 7 wherein the antibodies are at least of the human IgG isotype.

9. A composition comprised of at least one compound according to any one of claims 1 to 8, wherein said compound is combined with a pharmaceutically acceptable carrier.

10. The composition according to claim 9, wherein said carrier solubilizes said compound in an alcohol or polyol solvent.



May 16, 2005

"STATEMENT UNDER ARTICLE 19(1)"

RE: International Application N° PCT/CA2004/002003
International filing date: November 22, 2004
Applicants: Prometic Biosciences Inc. et al.


Claim 1 is amended to better define R_1 to R_4 .

Claim 4 is amended to introduce the word "and" before the last word of the claim.

Claim 7 is amended to remove the last, redundant, period ".".

Yours very truly,

GOUDREAU GAGE DUBUC


Alain M. Leclerc

AML/hl

General Partnership
Patent and Trademark Agents

www.ggd.com

Montreal

Stock Exchange Tower

Suite 3400

P.O. Box 242

800 Place Victoria

Montreal, Canada H4Z 1E9

Telephone (514) 397-7602

Fax (514) 397-4382

Toll Free 1-800-361-6266

(Quebec and Ontario only)

Quebec City

140 Grande Allée Est

Suite 800

Quebec, Canada G1R 5V8

Telephone (418) 640-2000